新型药物-放疗联合早期临床试验的挑战与机遇:NRG Oncology、美国放射肿瘤学会、美国放射学会、Sarah Cannon研究所和美国放射肿瘤学学院的建议
本文由NRG Oncology发育治疗与放疗分委员会组织多学科专家组,针对新型药物-放疗联合早期临床试验的设计障碍进行政策综述,指出其与药物-药物联合开发不同且常被忽视的挑战,并提出可能缓解或消除这些障碍的潜在解决方案,举例说明可促进高效评估的特定临床试验设计。
要点
- 早期药物-放疗联合试验设计面临独特挑战,常被忽视且不同于药物-药物联合开发。
- 本文倡导可能缓解或消除部分障碍的潜在解决方案。
- 提供可促进新型药物-放疗联合高效评估的特定临床试验设计示例。
核心结论
- 早期药物-放疗联合试验设计存在常被忽视的独特挑战,本文倡导潜在解决方案并提供可促进高效评估的特定试验设计示例。
研究设计与样本
- 政策综述,由NRG Oncology发育治疗与放疗分委员会组织多学科研究者小组。
临床应用与阅片要点
- 作者倡导可能缓解或消除早期药物-放疗联合试验设计障碍的潜在解决方案。
- 作者提供可促进新型药物-放疗联合高效评估的特定临床试验设计示例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This Policy Review elucidates some of the many challenges associated with study design for early phase trials combining radiotherapy with novel systemic agents, which are distinct from drug-drug combination development and are often overlooked. We also advocate for potential solutions that could mitigate or eliminate some of these barriers, providing examples of specific clinical trial designs that could help facilitate efficient and effective evaluation of novel drug-radiotherapy combinations.
引用
- Zumsteg ZS, Sheth S, Jabbour SK, et al. Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO). Lancet Oncol. 2024. PMID: 39362260. doi:10.1016/S1470-2045(24)00264-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。